Furthermore, several studies have demonstrated that HMGA2 participates in 5-FU resistance in some malignancies, such as CRC [39, 41, 42], breast cancer [43, 44], and liver cancer [45]. This evidence concerns the gene HMGA2 and colorectal carcinoma.